Serina Therapeutics, Inc. - SER STOCK NEWS

Serina Therapeutics (NYSE American: SER) announced that their Chief Development Officer, Randall Moreadith, MD, PhD, will present at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston. The presentation focuses on their proprietary POZ-lipid technology, which shows promising results in improving lipid nanoparticle (LNP) formulations.

Key findings demonstrate that POZ-lipid did not trigger IgM or IgG antibody responses after repeated administration in animal testing. This contrasts with conventional PEG-lipids, which produced strong antibody responses. The absence of immune response to POZ-lipid suggests potential for developing safer LNP formulations, particularly significant given that anti-PEG antibody responses have been linked to hypersensitivity reactions in mRNA-based vaccine recipients.

Serina Therapeutics (NYSE American: SER) has secured a $10 million equity financing from JuvVentures (UK) to advance SER-252 (POZ-apomorphine) into Phase 1 clinical trials for advanced Parkinson's disease patients in H2 2025. The financing involves issuing one million shares at $10 per share, representing a 120% premium to the November 26 closing price. The funding will be delivered in two $5 million tranches, with the first received on November 27, 2024, and the second due by January 31, 2025.

Serina Therapeutics (NYSE American: SER) reported Q3 2024 financial results and business updates. The company's revenue was $14,000 from NIH grants, down from $29,000 in Q3 2023. Operating expenses increased to $5.3 million from $1.5 million year-over-year. Despite reporting net income of $1.4 million ($0.16 per basic share), the company faces substantial going concern issues with only $3.2 million in cash as of September 30, 2024. Key highlights include a partnership with Enable Injections for their lead candidate SER-252, targeting advanced Parkinson's disease through their POZ Platform™ technology.

Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to three new non-executive employees. The grants, totaling 60,500 shares of common stock, were made on November 6, 2024, with exercise prices matching the closing stock price on that date. These options were approved as employment inducement awards under NYSE American's Company Guide Section 711(a). The options will vest over three years, with one-third vesting after the first year and the remaining two-thirds vesting in 24 monthly installments, contingent on continued employment.

Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company, announced its participation in the 14th Annual Injectables Summit in Boston, MA. The company's Chief Development Officer, Randall Moreadith, MD, PhD, will present alongside Enable Injections' Chief Commercial Officer Matthew Huddleston.

Their joint presentation, titled 'Patient-enabled Therapy for Advanced Parkinson's Disease', will focus on the collaboration between Serina's SER-252 and Enable Injections' enFuse Wearable Drug Delivery Platform. This partnership aims to provide advanced Parkinson's Disease patients with life-changing therapeutics through comfortable and convenient delivery methods.

Serina Therapeutics is known for developing its proprietary POZ Platform™ drug delivery technology, which is likely to be a key component in this collaborative effort to improve patient care and treatment outcomes.

Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Steve Ledger, Serina's Interim CEO, will present on September 11, 2024, at 12:00 p.m. ET.

Serina is known for developing its proprietary POZ Platform™ drug delivery technology. Investors and interested parties can access a live webcast of the presentation through the Investor section of Serina's website. An archived replay will also be available for a time after the event.

This presentation offers an opportunity for Serina to showcase its innovative technology and progress to a global investment audience, potentially impacting its stock performance and investor interest.

Serina Therapeutics (NYSE American: SER) reported Q2 2024 financial results and business highlights. Key points include:

1. Partnership with Enable Injections for SER-252 development in Parkinson's disease
2. Presentation of POZ-lipid immunogenicity data showing potential safety improvements for mRNA-LNP formulations
3. Appointment of Dr. Srini Tenjarla as SVP of CMC & Formulation

Financial highlights:
- Cash and equivalents: $6.1 million as of June 30, 2024
- Q2 2024 revenues: $51,000 (vs $7,000 in Q2 2023)
- Q2 2024 operating expenses: $3.9 million (vs $1 million in Q2 2023)
- Q2 2024 net income: $5.2 million or $0.61 per share (basic)

The company faces going concern considerations due to projected cash flows.

Serina Therapeutics (NYSE American: SER) is set to present groundbreaking data on its POZ-lipid technology at the 4th Annual mRNA-Based Therapeutics Summit in Boston, MA, from July 29-31, 2024. Dr. Randall Moreadith, Chief Development Officer, will showcase how this innovative approach could enhance the safety and efficacy of mRNA-LNP formulations.

The presentation, scheduled for July 29 at 9:00 AM ET, will highlight that POZ-lipid does not induce IgM or IgG antibody responses, even with repeated dosing in animal models. This is a significant advancement over current PEG-lipids used in mRNA vaccines, which can trigger anti-PEG antibody responses linked to serious adverse events, including life-threatening anaphylaxis.

Serina's technology has the potential to mitigate these risks, potentially improving the overall safety profile of mRNA-LNP medicines and opening new possibilities in the rapidly evolving field of mRNA therapeutics.

Serina Therapeutics (NYSE American: SER) has appointed Dr. Srini Tenjarla as the new Senior Vice President of CMC and Formulation. Dr. Tenjarla brings over 20 years of experience in drug development, joining from Takeda Pharmaceuticals where he was Vice President and Head of Drug Product Development and Process Chemistry Development/Outsourcing. He previously held leadership roles at Shire Pharmaceuticals.

Dr. Tenjarla's expertise spans formulation development across multiple modalities, including solid oral, injectables, controlled release, and ophthalmic formulations. He has a proven track record in advancing programs through clinical phases to NDA/BLA submission and approval. Dr. Tenjarla holds a Ph.D. in Pharmaceutical Sciences from the University of Houston and is recognized as a subject matter expert in formulation.